arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

REPLIGEN CORP

RGEN
$163.85 ▲ +4.38 (+2.75%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
18 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
60
Health
Fair
Neutral
auto_awesome

Analytical Summary

REPLIGEN CORP shows mixed fundamentals. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $9.2M
Dividend Yield
Revenue Growth 16.4%
Op. Margin 7.5%
ROIC 1.6%
FCF / Share None
Trailing P/E 188.3x
Price / Book 4.4x
FCF Yield
Debt / Equity 0.26
info Valuation on last close. End-of-day price, Aug 7, 2026.

18-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$738.26M
↑ +16.4%
Net Income Profit after all expenses
$48.89M
↑ +291.6%
Operating Margin Operating profit as % of sales
7.5%
↑ +235.0% 50th
FCF / Share Free cash flow per share
$0.76
↓ -24.1%
Long-Term Debt Long-term obligations
$542.21M
↑ +3.2%

Health Breakdown

Profitability
57
Returns
48
Financial Health
65
Cash Quality
85

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 18 years · 68 quarters